Botanix Pharmaceuticals / Sofdra Launch

Quote

realbotsalesperson said:
Refills are above 97% month on month. Clients are not in the habit of cancelling, mainly because Sofdra is working.

Can't give you exact figures, but let's just say somewhere in between 3% - 7% of the market is already ours. Have seen multiple big wigs from places I cannot say meet with management. TO is coming.
Click to expand...
Interesting - do you mean 3-7% of prescribers or actual patient TAM? That would be a huge number already. Wondering what base you’re using.
 








Let’s all stay grounded—there’s no need for exaggeration or speculation. Since the end of December 2024, we've reached over 18,000 patients, and based on current momentum, we’re on track to hit around 70,000 by year’s end. The product is performing exceptionally well and demand continues to grow. We're not just aiming to meet our sales targets—we’re on pace to exceed them. That success will translate into the recognition and rewards we expect.


I know this forum is closely followed by a number of Australian investors, and as I’ve said before, the upcoming sales results due in July will back this up—clear, hard evidence of what we’ve been saying all along.
 

























Write your reply...
Top Bottom
Back
Quote